Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jie Zheng
University of Texas Dallas, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Clearnano, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Clearnano is commercializing gold nanoparticles for use in kidney function imaging. This NIH project seeks to demonstrate how to use gold nanoparticles to study kidney imaging functions. This NIH project resulted in a utility patent application for a method to use nanoparticles in kidney imaging and know-how. Dr. Zheng’s financial interest in Clearnano could significantly and directly affect the conduct of this research project because Clearnano has submitted an SBIR proposal that intends to use the method described in the patent application.
Surface chemistry for high-contrast fluorescence kidney imaging
One in 10 adults in the United States suffers from a variety of kidney diseases; thus developing low- cost and high-sensitivity imaging techniques that can advance our fundamental understandings of underlying mechanisms of kidney diseases and drug development will be highly desired but remains highly challenging. We aim to develop a new class of near infrared (NIR)-emitting nanoparticles with desired in vivo behaviors that can significantly enhance kidney-imaging contrast more than one order of magnitude over current fluorescent contrast agents while allow imaging-time window to be optimized for different imaging requirements. Success of the proposed work will enable in vivo fluorescence imaging to serve as a practical tool to promote preclinical kidney research and catalyze new paradigm shifts in imaging guided kidney surgery. 1
Filed on August 23, 2017.
Tell us what you know about Jie Zheng's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.